Skip to main content

Innovations within Precision Oncology: Evolution of a Biomarker - a Case Study of KRAS-G12C

Innovations within Precision Oncology:  Evolution of a Biomarker; a Case Study of KRAS-G12C


On-Demand Webinar


Quest Diagnostics Oncology Associate Medical Director Mark Kruzel, MD, MBA recently discussed the evolving biomarker landscape for non-small cell lung cancer (NSCLC) during the University of Miami Pathology Conference. Dr. Kruzel’s presentation raises awareness of KRAS G12C as an actionable biomarker for NSCLC, and reviews available methods and clinical guidance recommendations for biomarker testing at the diagnosis of NSCLC. 


Mark Kruzel, MD,